Fredun Pharmaceuticals
₹672.00
-21.45 (-3.09%)
21 November, 2024 19:26 BSE: 539730
NSE: FREDUNISIN: INE194R01017
Start SIP in Fredun Pharmaceuticals
Start SIPFredun Pharmaceuticals Performance
Day Range
52 Week Range
Fredun Pharmaceuticals Technicals
EMA & SMA
Current Price
₹672.00
-21.45 (-3.09%)
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- ₹710.29
- 50 Day
- ₹741.60
- 100 Day
- ₹771.92
- 200 Day
- ₹805.15
- 20 Day
- ₹708.97
- 50 Day
- ₹748.44
- 100 Day
- ₹786.76
- 200 Day
- ₹811.10
Fredun Pharmaceuticals Resistance and Support
PIVOT
₹678.04
Resistance | |
---|---|
First Resistance | 697.87 |
Second Resistance | 723.73 |
Third Resistance | 743.57 |
RSI | 34.15 |
MFI | 36.81 |
MACD Single Line | -17.62 |
MACD | -19.10 |
Support | |
---|---|
First Support | 652.17 |
Second Support | 632.33 |
Third Supoort | 606.47 |
Fredun Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 8,304 | 610,095 | 73.47 |
Week | 10,996 | 753,973 | 68.57 |
1 Month | 7,568 | 561,020 | 74.13 |
6 Month | 7,460 | 582,649 | 78.1 |
Fredun Pharmaceuticals Result Highlights
Fredun Pharmaceuticals Forecast
Price Estimates
2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)
Fredun Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-10-26 | Quarterly Results | |
2024-10-03 | Others | inter alia consider issue and allotment of Unsecured Foreign Currency ConvertibleBonds (FCCBs), in accordance with the provisions of the SEBI Regulations, 2018 and the Companies Act, 2013. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method. |
2024-07-29 | Quarterly Results | |
2024-05-07 | Audited Results & Final Dividend | |
2024-02-14 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2024-09-23 | FINAL | Rs.0.70 per share(7%)Final Dividend |
2023-09-22 | FINAL | Rs.0.70 per share(7%)Final Dividend |